Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity

Hoffman SJ, Sadrolashrafi K, Mobini N. Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity. Case Rep Dermatol Med.[...]

Prediction Markets in Dermatology: Ethical Considerations for Physicians

Jonnalagadda A, Desai AD, Zhou AE, Grant-Kels JM. Prediction Markets in Dermatology: Ethical Considerations for Physicians. Clin Dermatol. 2026 Sep 3:S0738-081X(26)00226-9. doi: 10.1016/j.clindermatol.2026.09.001. Epub ahead[...]

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults

Gregoire S, Dewey E, Biba U, Sanchez K, Englander H, Salloum L, Ershadi S, Cheng D, McIntosh BA, Zangenah N, Vazquez-Machado M, Parekh A, Kam[...]